BBD24 improved cisplatin sensitivity in vitro. HOS cells were treated with BBD24 and/or cisplatin for 72h, then MTT assay was used to measure the cell viability. (A, B) HOS cells were treated with different concentrations of BBD24 or cisplatin. (C) HOS cells were treated with BBD24 (2 μg/ml) and/or cisplatin (1 μg/ml). (D) Cell viability of HOS in cisplatin group and cisplatin+BBD24 group. (E, F) IC50 of BBD24, cisplatin, cisplatin+BBD24 (1 μg/ml) and cisplatin+BBD24 (2 μg/ml). Results were expressed as means ± SD of three independent experiments. * P<0.05.